NIH-Funding

Wearable Alcohol Biosensors (R43/R44 Clinical Trial Optional)

NIH Funding Announcements - Tue, 11/28/2017 - 11:55
Funding Opportunity PAR-18-204 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to encourage Small Business Innovation Research (SBIR) applications from eligible small business concerns proposing to design and produce a non-invasive, discreet, wearable device to monitor blood alcohol levels in real time. Methods that quantify alcohol in blood or interstitial fluid as opposed to detection of alcohol that has exuded through the skin are of particular interest.
Categories: NIH-Funding

NIDDK Exploratory Clinical Trials for Small Business (R44 Clinical Trial Required)

NIH Funding Announcements - Tue, 11/28/2017 - 11:54
Funding Opportunity PAR-18-108 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Innovation Research (SBIR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The projects must focus on products related to the mission and goals of the NIDDK and may evaluate drugs, biologics, or devices, as well as surgical, behavioral or rehabilitation therapies. The purpose of this Funding Opportunity Announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Innovation Research (SBIR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The projects must focus on products related to the mission and goals of the NIDDK and may evaluate drugs, biologics, or devices, as well as surgical, behavioral or rehabilitation therapies.
Categories: NIH-Funding

Predicting Behavioral Responses to Population-Level Cancer Control Strategies (R21 Clinical Trial Optional)

NIH Funding Announcements - Tue, 11/28/2017 - 11:44
Funding Opportunity PAR-18-024 from the NIH Guide for Grants and Contracts. The goal of this funding opportunity announcement (FOA) is to facilitate research to identify individual influences on the effectiveness of population-level strategies that target cancer-related behaviors. We seek to encourage collaborations among scientists with expertise in health policy research and implementation, as well as investigators in scientific disciplines that have not traditionally conducted cancer or policy research, such as: psychological science (e.g., social, developmental); affective and cognitive neuroscience; judgment and decision-making; consumer behavior and marketing; organizational behavior; sociology, cultural anthropology; behavioral economics; linguistics; and political science.
Categories: NIH-Funding

Tobacco Use and HIV in Low and Middle Income Countries (R01 Clinical Trial Optional)

NIH Funding Announcements - Tue, 11/28/2017 - 11:42
Funding Opportunity PAR-18-023 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage research focused on tobacco use and human immunodeficiency virus (HIV) infection in low and middle income countries (LMICs). In particular, applications are encouraged that focus on the development and evaluation of tobacco cessation interventions tailored to HIV positive populations, including those with co-morbidities such as tuberculosis (TB), in low-resource settings in LMICs. This FOA provides funding for research planning, intervention delivery, and follow-up activities.
Categories: NIH-Funding

Revision: NIH Policy and Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research

NIH Funding Announcements - Tue, 11/28/2017 - 11:03
Notice NOT-OD-18-014 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Notice of Expiration of PAR-16-396 "NICHD Laboratory of Developmental Biology (R24)"

NIH Funding Announcements - Tue, 11/28/2017 - 10:20
Notice NOT-HD-17-031 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Tobacco Use and HIV in Low and Middle Income Countries (R21 Clinical Trial Optional)

NIH Funding Announcements - Tue, 11/28/2017 - 09:57
Funding Opportunity PAR-18-022 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage exploratory/developmental research focused on tobacco use and human immunodeficiency virus (HIV) infection in low and middle income countries (LMICs). In particular, applications are encouraged that focus on the development and evaluation of tobacco cessation interventions tailored to HIV positive populations, including those with co-morbidities such as tuberculosis (TB), in low-resource settings in LMICs. This FOA provides funding for research planning, intervention delivery, and follow-up activities.
Categories: NIH-Funding

Collaboratory on Research Definitions for Cognitive Reserve and Resilience to Alzheimer's Disease (R24 - Clinical Trial Not Allowed)

NIH Funding Announcements - Tue, 11/28/2017 - 03:30
Funding Opportunity RFA-AG-18-024 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to provide infrastructure support to advance development of operational definitions and approaches for the study of the concepts of cognitive reserve and resilience to Alzheimers disease and related dementias (ADRD) and age-related cognitive decline. The infrastructure support will facilitate a collaborative research network through meetings, conferences, small-scale pilots, and dissemination activities to foster development and champion use of state-of-the-art definitions, uniform nomenclature, and validated approaches that will be key to the advancement of research on maintenance of brain and cognitive health and treatment and/or prevention of ADRD.
Categories: NIH-Funding

Innovative Research in HIV in Kidney, Urology, and Hematology (R01 Clinical Trial Optional)

NIH Funding Announcements - Tue, 11/28/2017 - 03:13
Funding Opportunity RFA-DK-17-037 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for innovative research projects examining the basic and clinical aspects of HIV infection, treatment, and long-term sequelae as they relate to the mission of the Division of Kidney, Urologic and Hematologic Diseases within NIDDK (KUH/NIDDK).
Categories: NIH-Funding

NHLBI Career Transition Award for Intramural Fellows (K22) (Clinical Trials Required)

NIH Funding Announcements - Tue, 11/28/2017 - 02:57
Funding Opportunity PAR-18-424 from the NIH Guide for Grants and Contracts. The purpose of the NHLBI Career Transition Award (K22) program is to provide highly qualified postdoctoral fellows in the NHLBI Division of Intramural Research the opportunity to transition their research programs as new investigators to extramural institutions. To achieve these objectives, the NHLBI Career Transition Award will support two phases of research: a mentored intramural phase (up to two years) and an extramural phase (three years), for a total of five years of combined support. Transition from the intramural phase of support to the extramural phase is not automatic. Approval of the transition will be based on the success of the awardee's research program during the mentored phase as determined by an NHLBI progress review, which will include an evaluation of a research plan to be carried out at the extramural institution. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (FOA #).
Categories: NIH-Funding

NHLBI Career Transition Award for Intramural Fellows (K22) (No Independent Clinical Trials)

NIH Funding Announcements - Tue, 11/28/2017 - 02:57
Funding Opportunity PAR-18-416 from the NIH Guide for Grants and Contracts. The purpose of the NHLBI Career Transition Award (K22) program is to provide highly qualified postdoctoral fellows in the NHLBI Division of Intramural Research the opportunity to transition their research programs as new investigators to extramural institutions. To achieve these objectives, the NHLBI Career Transition Award will support two phases of research: a mentored intramural phase (up to two years) and an extramural phase (three years), for a total of five years of combined support. Transition from the intramural phase of support to the extramural phase is not automatic. Approval of the transition will be based on the success of the awardee's research program during the mentored phase as determined by an NHLBI progress review, which will include an evaluation of a research plan to be carried out at the extramural institution. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (TEMP-229).
Categories: NIH-Funding

NIDDK Multi-Center Clinical Trial Cooperative Agreement (U01 Clinical Trial Required)

NIH Funding Announcements - Tue, 11/28/2017 - 02:52
Funding Opportunity PAR-18-415 from the NIH Guide for Grants and Contracts. This FOA invites applications for investigator-initiated, multi-center clinical trials involving three or more clinical centers. Proposed trials should be hypothesis-driven, have the potential to change clinical practice and/or public health, and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this FOA. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see PAR-18-xxx ). Consultation with NIDDK Scientific/Research staff is strongly encouraged prior to the submission of either a U34 or U01 application.
Categories: NIH-Funding

NIDDK Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)

NIH Funding Announcements - Tue, 11/28/2017 - 02:52
Funding Opportunity PAR-18-414 from the NIH Guide for Grants and Contracts. This FOA invites applications for investigator-initiated, multi-center observational studies involving three or more clinical centers. Proposed studies should be hypothesis-driven and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this FOA. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see PAR-18-xxx ). Consultation with NIDDK Scientific/Research staff is strongly encouraged prior to the submission of either a U34 or U01 application.
Categories: NIH-Funding

NIDDK Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)

NIH Funding Announcements - Tue, 11/28/2017 - 02:52
Funding Opportunity PAR-18-423 from the NIH Guide for Grants and Contracts. NIDDK supports investigator-initiated, multi-center (three or more centers) clinical studies through a two-part process that may include an implementation planning cooperative agreement (U34). The U34 is designed to: 1) Permit early peer review of the rationale for the proposed clinical study; 2) Permit assessment of the design and protocol of the proposed study; 3) Provide support for the development of documents needed for the conduct of the study, including a manual of operations; and 4) Support the development of other essential elements required for the conduct of the clinical study. The proposed clinical study should be hypothesis-driven and focus on a disease relevant to the mission of NIDDK. Consultation with NIDDK scientific staff is strongly encouraged prior to the submission of the U34 application.
Categories: NIH-Funding

By: KK

WriteEdit-Grant Questions Blog - Tue, 11/28/2017 - 02:25

Let’s hope so!

Categories: NIH-Funding

By: writedit

WriteEdit-Grant Questions Blog - Tue, 11/28/2017 - 02:15

We won’t know for sure until the FY18 budget passes, but you should be in good shape with a 9th percentile application.

Categories: NIH-Funding

By: KK

WriteEdit-Grant Questions Blog - Tue, 11/28/2017 - 02:08

Thanx for the quick reply. My main question has to do with the 2018 payline and if it is likely for NCI to have the same payline as 2017?

Categories: NIH-Funding